Top of page

Alain Kuyumjian



Biodesix $72 million IPO
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…
Back to top